Compare Illumina, Inc. (ILMN) vs Impinj Inc (PI) Price & Performance

Illumina, Inc.Trade

Impinj IncTrade

Price performance (Past 24H)

Key statistics

Illumina, Inc. vs Impinj Inc — how do they compare? Illumina, Inc. trades at $192.51 (market cap $27.94B), while Impinj Inc trades at $135.93 (market cap $4.19B). The key difference: Illumina, Inc. is far larger — about 6.7× Impinj Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Impinj Inc nearer its low. Which is the better fit depends on your goals.

	ILMN	PI
Market Cap	$27.94B	$4.19B
Sector	Health	Technology
52-Week High	$194.33	$241.91
52-Week Low	$91.00	$91.34
Enterprise Value	$29.33B	$4.33B

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Illumina, Inc.

No Aura AI signal available yet.

Impinj Inc

Impinj (PI) trades at $137.72, down 0.33% on the day, with a bearish technical signal from moving averages despite recent earnings beats. The company reported Q1 2026 EPS of $0.14, exceeding expectations, but maintains negative net income margins and high valuation multiples. Recent insider sales and mixed news flow highlight investor caution amid specialized RFID market positioning.

PI offers growth potential in RFID technology with strong analyst buy ratings (72.7% consensus) and a $167.50 price target, but faces significant risks from profitability challenges, high debt-to-asset ratio (51.52% in 2025), and competitive pressures. The stock's outlook hinges on execution improvement and market expansion to justify current valuations.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

ILMN

ARKG and GNOM ETFs offer different genomic bets with varied risk and returns in 2026.24/7 Wall Street · 10 hours agoNeutral Cancer biomarkers market to hit $54.48B by 2032, driven by tech advances and Asia-Pacific growthResearchandmarkets.Com · 4 days agoBullish New report details 1,230+ bioinformatics deals, revealing market trends and deal structures through 2026Researchandmarkets.Com · 4 days agoNeutral View details →

View details →

About Illumina, Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

About Impinj Inc

Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.